Aclaris Therapeutics, Inc. (ACRS) stock
ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30138% above fair value
$3.38−0.23 (-6.24%)
Close on Nov 17, 2026Market cap $497.53MP/E –Yield –
Aclaris Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Aclaris Therapeutics's price to book ratio was 4.9× on Nov 11, 2026, against 2.6× a year earlier. Over the last 5 years it ranged from 0.4× to 6.8×, with a median of 3.0×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 4.9× | +2.2 |
| 2025 | Dec 31, 2025 | 2.7× | +1.4 |
| 2024 | Dec 31, 2024 | 1.4× | +0.9 |
| 2023 | Dec 29, 2023 | 0.5× | −4.3 |
| 2022 | Dec 30, 2022 | 4.8× | +0.7 |
| 2021 | Dec 31, 2021 | 4.1× | −2.7 |
| 2020 | Dec 31, 2020 | 6.8× | +5.9 |
| 2019 | Dec 31, 2019 | 0.9× | −0.6 |
| 2018 | Dec 31, 2018 | 1.6× | −1.5 |
| 2017 | Dec 29, 2017 | 3.1× | −4.1 |
| 2016 | Dec 30, 2016 | 7.2× | – |
See a number that looks wrong?